ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
60 announcements with these filters
Religare Enterprises Limited held its 42nd Annual General Meeting on September 24, 2026, where members adopted financial statements and approved the re-designation of Mr. Arjun Lamba.
Religare Enterprises' subsidiary, Care Health Insurance Limited, has allotted non-convertible debentures aggregating to ₹100 Crore. These securities will be listed on the NSE.
Religare Enterprises Limited has approved the continuation of Mr. Rajender Mohan Malla as the Non-Executive Chairperson for the quarter ending December 31, 2026.
Religare Enterprises informed that the Securities Appellate Tribunal dismissed its appeal against an earlier SEBI order. The company is sharing this legal update for record.
India Ratings affirmed the existing credit rating and assigned a new subordinated debt rating of IND AA-/Stable to Care Health Insurance, a material subsidiary of Religare.
Religare Enterprises Limited has scheduled its 42nd Annual General Meeting for September 24, 2026, to be held via Video Conferencing.
Ashish Dhawan acquired 38,00,000 equity shares of Religare Enterprises Limited via an open market purchase. This transaction increases his shareholding in the company.
Religare Enterprises Limited acquired equity shares of its wholly-owned subsidiary, Religare Broking Limited, through a rights issue for ₹100.00 Crore.
Religare Q1FY27 shows strategic focus on core segments. Consolidated revenue grew 26% YoY to ₹2,358 Cr, though PAT remains negative at ₹46.9 Cr due to reporting standard transitions and investment modes.
Religare Enterprises Limited announced a change in designation for Mr. Arjun Lamba. He has transitioned from Wholetime Director to Executive Director.
Religare reported Q1 FY27 consolidated revenue of Rs. 2,358.4 Cr, up 26% YoY, driven by strong performance in the Insurance segment. Net profit turned into a loss of Rs. 46.9 Cr.
Religare Enterprises Ltd reported revenue from operations of ₹2.5 Cr (+1150.0% YoY) and a net loss of ₹9.6 Cr for Q1 FY27.
Religare Enterprises Ltd reported revenue from operations of ₹2,353 Cr (+25.7% YoY) and a net loss of ₹47 Cr for Q1 FY27.
Religare Enterprises Limited has amended its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, in compliance with SEBI Regulations.
Religare Enterprises has granted 13,195 stock options under its ESOP Scheme 2019. The options vest in five equal annual instalments of 20% each.
Religare Enterprises has scheduled a board meeting on August 12, 2026. The board will consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Religare Enterprises announced that its subsidiary, Care Health Insurance Limited, has allotted non-convertible debentures aggregating to ₹200 Crore.
Religare Enterprises Limited has allotted 35,00,000 equity shares following the conversion of an equivalent number of warrants. This capital structure change increases the total paid-up share capital.
Religare Enterprises Limited allotted 35,00,000 equity shares to Puran Associates Private Limited (Promoter Group). This follows the conversion of warrants at a price of Rs. 235 per share.
Religare Enterprises' subsidiary, MIC, has surrendered its Insurance Web Aggregator license to the IRDAI. The company confirms no material impact as the unit is not currently operating.
Religare Enterprises announced that SEBI has disposed of the Interim Order and Show Cause Notice dated June 19, 2024, without issuing any directions against the company.
Religare Enterprises announced the resignation of Anuj Jain, Company Secretary and Compliance Officer, effective from the close of business hours on July 31, 2026.
Religare Enterprises Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI requirements.
Religare Enterprises subscribed to a rights issue by its subsidiary, Care Health Insurance, for Rs. 119.69 Crore. The investment supports the subsidiary's expansion and solvency requirements.
Religare Enterprises approved the continuation of Mr. Rajender Mohan Malla as Non-Executive Chairperson. His term is extended for the July-September 2026 quarter on a rotational basis.
Religare Enterprises received 'no objection' for its demerger scheme. The restructuring, subject to statutory approvals, aims to separate its businesses.
ICRA has reaffirmed the [ICRA]BBB- (Stable) rating for Religare Housing's bank lines. The rating applies to a rated amount of ₹400 Crore.
Religare Enterprises appointed Pavan Kumar Gupta as MD and CEO of its subsidiary RHDFCL. The appointment is effective from July 1, 2026.
Religare Enterprises Limited allotted 83,43,263 equity shares following the conversion of warrants. This increases the company's total paid-up share capital to 34,12,33,742 shares.
Religare Enterprises allotted 83,43,263 equity shares following warrant conversions, receiving ₹147.05 Crore in funds. This conversion increases the company's total paid-up share capital.